Data Sheet (Cat.No.T12244)

TargetMol

Norverapamil

Chemical Properties



CAS No. : 67018-85-3

Formula: C26H36N2O4

Molecular Weight: 440.58

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	Norverapamil is a blocker of L-type calcium channel and an inhibitor of P-glycoprotein (P-gp) function .
Targets(IC50)	Calcium Channel,Drug Metabolite,P-gp
In vitro	Verapamil's R isomer and its metabolite norverapamil have substantially less calcium channel blocking activity yet were similarly active as verapamil at inhibiting macrophage-induced drug tolerance.?Our finding that verapamil inhibits intracellular M. tuberculosis growth and tolerance suggests its potential for treatment shortening.? Norverapamil, R-verapamil, and potentially other derivatives present attractive alternatives that may have improved tolerability[1].
In vivo	Norverapamil is?a major metabolite of verapamil, has terminal half-life, AUC and Cmax values of 9.4 hours, 260 ng?h/ml, and 41.6 ng/mL, respectively[2].

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.2697 mL	11.3487 mL	22.6974 mL
5 mM	0.4539 mL	2.2697 mL	4.5395 mL
10 mM	0.227 mL	1.1349 mL	2.2697 mL
50 mM	0.0454 mL	0.227 mL	0.4539 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Adams KN, et al. Verapamil, and its metabolite norverapamil, inhibit macrophage-induced, bacterial efflux pump-mediated tolerance to multiple anti-tubercular drugs. J Infect Dis. 2014 Aug 1;210(3):456-66.
Choi DH, et al. Effects of simvastatin on the pharmacokinetics of verapamil and its main metabolite, norverapamil, in rats. Eur J Drug Metab Pharmacokinet. 2009 Jul-Sep;34(3-4):163-8.
Wang J et al. A semi-physiologically-based pharmacokinetic model characterizing mechanism-based auto-inhibition to predict stereoselective pharmacokinetics of verapamil and its metabolite norverapamil in human. Eur J Pharm Sci. 2013 Nov 20;50(3-4):290-302.

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481